Following the release of clinical study data, TransCode Therapeutics Inc. (NASDAQ: RNAZ) soared 38.53% to $1.51 in pre-market trading hours on the most recent check Wednesday.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
What information did RNAZ share?
Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma were released today by TransCode Therapeutics (RNAZ).
- In a mouse model of pancreatic cancer, TransCode Therapeutics assessed the bioactivity of TTX-MC138, its primary treatment candidate.
- In the experiment, mice with human pancreatic tumors implanted in their pancreas received TTX-MC138 once every week for 10 weeks.
- By effectively suppressing its target, microRNA-10b (miR-10b), as evaluated by qRT-PCR, a widely used technique for determining gene expression, the medication showed a pharmacodynamic response.
- A potential substitute biomarker of treatment effectiveness, serum miR-10b, was down-regulated by TTX-MC138 in this investigation.
- In 40% of the rats given TTX-MC138 treatment, full responses—defined as total disease regression and sustained survival without recurrence—occurred.
- More research is being done to pinpoint the ideal dosage and therapeutic window for pancreatic cancer.
How encouraging are the results for RNAZ?
The therapeutic usefulness of TTX-MC138 may now also be extended to pancreatic cancer as a result of these recent discoveries. The efficacy of TTX-MC138 to induce durable regression of metastatic breast cancer in murine models had already been demonstrated, so RNAZ’s next step was to assess the applicability of its therapeutic approach in a pancreatic cancer model with an eye toward evaluating other solid tumor types that express miR-10b.
The results of this pancreatic cancer research, as with earlier ones, justify the development of TTX-MC138 in the clinic. These preclinical findings provide RNAZ further assurance that TTX-MC138 has the potential to develop into a cutting-edge, first-in-class therapeutic strategy for treating advanced solid tumors, which may eventually lead to better clinical results for patients.
How will RNAZ move forward?
TransCode Therapeutics (RNAZ) is taking a key step in the preclinical development process by demonstrating effective therapy utilizing its first-in-class RNA-targeted therapeutic candidate in a number of solid tumor models, greatly de-risking its strategy. For its planned Phase 0 first-in-human (FIH) clinical study using TTX-MC138 in cancer patients with advanced solid tumors, as RNAZ has previously mentioned, the company is on schedule to file an exploratory Investigational New Drug Application (eIND) this year.
